Emerging novel approaches to drug research and diagnosis of Parkinson’s disease

Authors: Xue-chu Zhen1, Hong-Yuan Chu2
1 Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, 215123 Suzhou, China
2 Center For Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA
Correspondence to: Xue-chu Zhen: zhenxuechu@suda.edu.cn, Hong-Yuan Chu: hongyuan.chu@vai.org,
DOI: 10.1038/s41401-020-0369-7
Received: 16 January 2020
Accepted: 17 January 2020
Advance online: 13 March 2020


Parkinson’s disease (PD) is one of the most common neurode-generative diseases. Genetic factors are involved in <10% of PD cases, while the majority of PD cases have no identifiable genetic factors. All these studies have revealed the heterogeneity of Parkinson’s disease both in pathogenesis and etiology [1, 2]. In the past decade, many well-designed longitudinal studies have clearly elucidated that environmental or behavioral factors can modify the risk of developing Parkinson’s disease and alter the pathological process of PD [2]. Moreover, many factors that were found to be associated with an altered risk of PD in epidemio-logical studies have been confirmed to be neuroprotective or neurotoxic to dopaminergic (DA) neurons in experimental animal models of PD.

Article Options

Download Citation

Cited times in Scopus